New UDI Requirements for Medical Devices
From 1 July 2026, Australia enters a significant new phase in the regulation of medical devices with the commencement of mandatory Unique Device Identification (UDI) requirements for selected products. The new requirements represent one of the most substantial changes to medical device traceability introduced by the Therapeutic Goods Administration (TGA) in recent years and align Australia's regulatory framework with internationally recognised UDI systems already established in major global markets.
The introduction of UDI is intended to improve the identification, traceability and lifecycle management of medical devices supplied in Australia. For manufacturers and sponsors, these requirements introduce additional regulatory obligations that must be incorporated into quality management systems, labelling processes, technical documentation and regulatory compliance activities.
For organisations operating within highly regulated environments, successful implementation depends on careful planning, cross-functional coordination and a thorough understanding of the applicable compliance timeframes.
What is Unique Device Identification?
Unique Device Identification is a globally recognised system that assigns a unique identifier to an individual medical device model. Each device is identified using a standardised code that enables the device to be accurately recognised throughout its entire lifecycle.
The UDI system consists of two key elements. The Device Identifier (UDI-DI) identifies the specific model of the device, while the Production Identifier (UDI-PI) contains production-specific information such as batch number, serial number, manufacturing date or expiry date where applicable. Together these identifiers provide significantly improved traceability compared with traditional product identification methods.
The identifier is presented in both human-readable and machine-readable formats on device labels and applicable packaging, allowing efficient scanning and integration into healthcare information systems.
Which Devices Are Affected From 1 July 2026?
The first mandatory implementation phase applies to higher-risk medical devices.
From 1 July 2026, mandatory UDI requirements apply to:
Class III medical devices
Class IIb medical devices
Lower-risk devices will transition progressively over subsequent years according to the TGA implementation schedule.
Current implementation dates include:
1 July 2027 – Class IIa medical devices
1 July 2028 – Class Is medical devices together with Class 3 and Class 4 in vitro diagnostic (IVD) medical devices
1 July 2029 – Class 1 and Class 2 IVD medical devices
This phased approach allows industry additional time to prepare while prioritising devices presenting higher levels of patient risk.
Why UDI Matters
Medical device identification has historically relied on product names, catalogue numbers and manufacturer information. Although functional, these approaches can create inconsistencies during recalls, adverse event investigations and inventory management.
UDI introduces standardised identification across manufacturers, healthcare providers and regulators.
Improved device identification delivers several important benefits, including:
stronger traceability throughout the supply chain
faster identification during recalls and field safety corrective actions
improved post-market surveillance
greater transparency for healthcare professionals and patients
improved integration with digital health systems
more accurate recording of implanted medical devices
The TGA has identified improved patient safety and enhanced visibility of medical devices as primary objectives of the Australian UDI framework.
Australian UDI Database
An important component of the new framework is the Australian UDI Database (AusUDID).
Manufacturers and sponsors are required to submit prescribed device information into the database in accordance with regulatory requirements. The database provides a central source of verified information relating to medical devices supplied within Australia.
Healthcare providers, regulators, consumers and other stakeholders can use the database to access current device information, improving transparency across the healthcare system.
As adoption increases, the database is expected to support hospital inventory management, electronic health records, post-market monitoring and more effective recall activities.
Regulatory Responsibilities for Manufacturers and Sponsors
Compliance with UDI requirements extends beyond simply placing a barcode on product packaging.
Manufacturers and sponsors should ensure that their regulatory systems adequately address:
assignment of compliant UDI identifiers
label and packaging updates
submission of required data to AusUDID
maintenance of accurate device information
integration of UDI requirements within quality management systems
ongoing change management processes
Organisations should also verify that technical documentation, manufacturing procedures and document control systems remain aligned with the applicable regulatory requirements.
UDI implementation frequently affects multiple departments including regulatory affairs, quality assurance, manufacturing, packaging engineering, information technology and supply chain management.
Integration Into Quality Management Systems
UDI should not be treated as a standalone labelling exercise.
Implementation often requires updates across numerous quality system processes, including document control, design changes, risk management, supplier management, production controls and post-market surveillance activities.
Procedures governing product release, complaint handling, vigilance reporting and recalls may also require revision to ensure UDI information is consistently captured and maintained throughout the product lifecycle.
Early integration into existing quality systems reduces implementation risk and supports long-term regulatory compliance.
Transition Planning
Although mandatory compliance has now commenced for Class III and Class IIb devices, organisations should continue reviewing their implementation programmes to identify any remaining compliance gaps.
Manufacturers supplying multiple device classifications should also prepare for future implementation phases rather than viewing each deadline independently. Developing a comprehensive UDI strategy now can minimise duplicated effort as additional product classes enter scope over the coming years.
Preparation should include regulatory assessments, gap analyses, verification of labelling systems, validation of data management processes and confirmation that required information can be accurately submitted and maintained within AusUDID.
Consent to Supply Provisions
Recognising that some organisations may require additional time to complete implementation, the TGA has introduced a streamlined UDI Consent to Supply process commencing on 1 July 2026.
Sponsors unable to fully comply with UDI requirements may apply for consent under specified circumstances, allowing continued importation and supply while achieving compliance. The revised process includes simplified application arrangements and reduced application fees compared with previous mechanisms. The TGA has also indicated it does not intend to take regulatory action while eligible applications submitted from 1 July 2026 are being assessed.
Looking Ahead
The commencement of mandatory UDI requirements represents an important milestone in Australia's evolving medical device regulatory framework. Beyond regulatory compliance, the system establishes a stronger foundation for traceability, post-market surveillance and patient safety throughout the healthcare sector.
For manufacturers and sponsors, UDI implementation should be approached as an integrated quality and regulatory initiative rather than a simple labelling project. Organisations that embed UDI into quality management systems, regulatory processes and product lifecycle management will be better positioned to maintain compliance as additional device classifications transition into scope over the coming years.
